key: cord-0936470-bhxcxyv2
authors: Shinkura, Reiko; Kang, Sujin; Arase, Hisashi; Toyama-Sorimachi, Noriko
title: The 49th Annual Meeting of the Japanese Society for Immunology: COVID-19 and Immunity
date: 2021-02-04
journal: Int Immunol
DOI: 10.1093/intimm/dxab004
sha: 48f026774ee54ee4e18bf2770548170d4dcd7d69
doc_id: 936470
cord_uid: bhxcxyv2

nan

Because of the restrictions caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19), the 49th Annual Meeting of the Japanese Society for Immunology was held online-only on 8 December 2020 and focused on the topic 'COVID-19 and Immunity'. We report here on two symposia ('Vaccines and Immunity' and 'Cytokine Storm and Related Disease') and also the Review Talk and Panel Discussion that took place at the end of the meeting.

Two speakers from the USA reported on the immune response to SARS-CoV-2 in patients with COVID-19. One Chinese scientist summarized the strategy of prevention and control in China and vaccine development. Lastly, two Japanese speakers presented data from ongoing vaccine projects against SARS-CoV-2. Here is a brief overview of each talk.

Akiko Iwasaki (Yale University School of Medicine, Howard Hughes Medical Institute, USA) discussed immune responses in patients with COVID-19, especially comparing moderate and severe diseases. In patients with severe disease, within 12 days of symptom onset, the viral load in the nasopharynx is maintained and drives inflammatory responses featuring cytokines such as IFN-α, IL-6 and IL-18, the blood levels of which may be predictive of mortality. Blood levels of neutrophils, eosinophils and inflammatory monocytes are highly associated with mortality. Since increased levels of interferons and cytokines, in other words 'cytokine misfiring', correlate with the viral load, Dr Iwasaki proposed that early treatment with recombinant interferon may be effective to reduce the viral load and prevent severe disease. She said 'Timing of interferon treatment is a key'.

The other topic discussed by Dr Iwasaki was the sex differences in immunity to SARS-CoV-2. She showed two major differences that affect disease outcomes: 'Men develop a greater inflammatory cytokine response than women' and 'Women develop better T-cell immunity than men'. Therefore, being male is one of the risk factors for severe COVID-19. Age is also one of the risk factors. However, older women develop better T-cell responses than older men do. At present, there is no answer for why sex differences in immunity to SARS-CoV-2 occur.

Alessandro Sette (La Jolla Institute for Immunology, University of California San Diego, USA) discussed immunological memory to SARS-CoV-2 6-8 months after infection. His group identified and analyzed 280 CD4-restricted and 523 CD8restricted epitopes from patients with COVID-19. The spike (S) protein is, without any doubt, a dominant antigen. For CD4-restricted epitopes, clear immunodominant regions are not in the receptor-binding domain (RBD) of the S-protein but are in neighboring regions such as the N-terminal domain (NTD) and the subunit that includes the fusion peptide and the cytoplasmic domain. This information is important for vaccine development, even if antibody and T-cell reactivity focus on independent antigenic regions of the S-protein. On the other hand, for the CD8 response, a broader region in the S-protein is recognized for epitopes. Dr Sette's group also clarified that common cold coronavirus homology does not predict CD4-restricted and CD8-restricted epitopes in patients with COVID-19, suggesting that SARS-CoV-2 infection creates a new repertoire.

The other topic discussed by Dr Sette was the duration of immunity to SARS-CoV-2. Although the kinetics of T cells, memory B cells and antibodies are distinct, 5 months after COVID-19, 89% of individuals still possess immune memory responses. In addition, from studies of acute phase cases, and as discussed by Dr Iwasaki, Dr Sette emphasized that 'the speed of adaptive immunity is key'. Especially, coordinated International Immunology doi:10.1093/intimm/dxab004 Advance Access publication 4 February 2021 antibody and T-cell adaptive immunity are protective. Age is another major COVID-19 risk factor. In older patients, the antibody and T-cell responses are poorly coordinated, partly because their repertoires of naive T cells may be limited.

George F. Gao (Chinese Center for Disease Control and Prevention, China) explained how China had achieved containment of the Wuhan outbreak and the following waves. He said that 'an effective commanding system led by state councils is crucial'. Now most areas of mainland China are virus-free and keep the containment status. 'Four earlies' are crucial: early detection, early reporting, early isolation and quarantine and early treatment. Indeed, Dr Gao showed that systematized virus genome analysis identified different imported viruses quickly and contained COVID-19 infection in restricted areas. Dr Gao also introduced the development of COVID-19 vaccines, in particular those under clinical evaluation in China, including a protein subunit vaccine and a tandem-repeat RBD single-chain dimer vaccine.

Hironori Nakagami (Osaka University, Japan) presented data about a plasmid DNA vaccine targeting the SARS-CoV-2 S-protein. In pre-clinical trials, both intra-dermal injection with a needleless injector and intra-muscular injection of the DNA vaccine encoding the S-protein were successful in increasing anti-S and anti-RBD antibodies with neutralizing activity in monkey and mouse models; injections were given three times at 2-week intervals. The cellular immunoreaction, as assessed by antigen-induced IFN-γ expression, was also up-regulated.

Importantly, intra-dermal injection of the DNA vaccine with the needleless injector does not require adjuvant to induce an antibody response and prevents distribution of the DNA vaccine in other tissues. Now a physician-initiated clinical trial is ongoing.

Ken J. Ishii (The University of Tokyo, Japan) discussed nucleic acid-based immuno-prophylaxis and immuno-therapy against COVID-19 but cautioned that 'haste makes waste'. Dr Ishii gave an overview of the advantages of mRNA vaccines: preparation can be rapid and large scale, the patient remains uninfected and there is no integration of viral nucleic acids. Disadvantages, such as instability or toxicity of free mRNA, have been overcome by mRNA vaccines being incorporated into lipid nanoparticles (LNPs). Dr Ishii showed that an LNP-mRNA vaccine encoding the RBD of SARS-CoV-2 S-protein induced both B-and T-cell responses in mouse and monkey models.

Interestingly, this LNP-mRNA vaccine (RBD) displayed strain-specific B-cell responses in mice. In C57BL/6 mice, LNP-mRNA vaccine (RBD) induced T-cell responses but did not induce RBD-specific antibody production, whereas Balb/c mice developed both T-cell responses and antibodies. However, formulation-modified LNP-vaccine (RBD) triggered a full antibody response in C57BL/6 mice. The rationale proposed by Dr Ishii is that 'reduction of the innate immune response to mRNA vaccine formulation may improve its immunogenicity'. Karikó et al. (1) demonstrated that nucleoside modification of mRNA decreases inflammatory responses, since Toll-like receptors (TLRs) do not recognize modified mRNAs such as methylated ones. Interferons were not induced by the modified mRNA vaccine, resulting in increased expression of protein antigens derived from the mRNA vaccine to induce a full antibody response. The mRNA vaccine can be modified further to improve its efficacy.

Day by day, new reports on COVID-19 are coming up. SARS-CoV-2 seems to confuse our immunity or disturb immune coordination. Especially, modulation of the innate immune response at the early phase of COVID-19 would be a key to tackle COVID-19, which is impacting economic and social life worldwide.

In the afternoon session of the symposium, five speakers presented research into the pathogenesis of the cytokine storm and related diseases. The aim of this session was to share recent scientific breakthroughs in our understanding of the pathogenesis of COVID-19 and related inflammatory diseases. This session focused on the potential development of new therapeutics for COVID-19. Recent mechanistic insights into inflammatory airway disease and their relevance to progressive lung diseases following respiratory viral infection (including COVID-19) pose a timely subject deserving of urgent attention.

Tadamitsu Kishimoto (iFReC, Osaka University) presented the clinical application of tocilizumab, which is an anti-IL-6 receptor antibody, and its impact on the pathogenesis of the COVID-19-induced cytokine storm. He presented the known therapeutic effects of tocilizumab on chronic immune diseases, such as rheumatoid arthritis and juvenile idiopathic arthritis. He also highlighted the efficacy of tocilizumab in treating cytokine storms, which are driven by the robust production of several pro-inflammatory cytokines by diverse types of cells. Excessive IL-6 production by activated macrophages has a major role in the pathogenesis of the cytokine storm induced by chimeric antigen receptor-modified T-cell therapy. He reported that the pathogenesis of this cytokine storm involved direct effects of IL-6 signaling in vascular endothelial cells, which formed a positive feedback loop for pro-inflammatory cytokine production and activation of the coagulation cascade. He presented clinical data that showed patients with severe COVID-19 symptoms had severe endothelial damage, as high as those with bacterial sepsis. Tocilizumab administration significantly helped these COVID-19 patients by reducing endothelial injury. Therefore, he demonstrated the therapeutic efficacy of tocilizumab in the COVID-19-induced cytokine storm.

Angiotensin-converting enzyme 2: from discovery to the heart of a pandemic storm Josef Penninger (University of British Columbia, Canada) had previously provided the first genetic evidence that

The 49th Annual Meeting of the Japanese Society for Immunology Page 3 of 4 angiotensin-converting enzyme 2 (ACE2) is an essential receptor for SARS-CoV-2 and provided a target to reduce lung injuries. Mechanistically, ACE2 catalytically removes the last amino acid of angiotensin II (Ang II), thereby counterbalancing the actions of ACE and Ang II and generating 'beneficial' downstream peptides such as the heptamer Ang 1-7. In the past year, it was shown that ACE2 expression is found in the kidney and intestinal epithelial cells and plays an active role in several kinds of tissue injury. Currently, ACE2 is recognized as the critical binding factor for the SARS-CoV-2 spike glycoprotein. This virus gains entry to host cells via ACE2, which is expressed by type 2 alveolar epithelial cells in the lungs and by cells in other tissues, including the heart and blood vessels. Human recombinant soluble ACE2 (hrsACE2) may provide a potential therapy to inhibit the entry of SARS-CoV-2. He presented new data using direct SARS-CoV-2 infection of engineered human blood vessel and kidney organoid models. His work demonstrated that treatment with hrsACE2 markedly attenuated the early phase propagation of SARS-CoV-2 in these engineered organoids.

Hisashi Arase (Osaka University) presented a novel factor that enhances SARS-CoV-2 infection during the development of severe pneumonia. He presented data from the screening of molecules that associate with the NTD of SARS-CoV-2 S-protein from a lung cDNA library. L-SIGN was identified as a receptor for the NTD of the S-protein. L-SIGN mediated membrane fusion and SARS-CoV-2 infection. Because ACE2 expression in the lung is low, L-SIGN-mediated infection seems to be involved in the pneumonia observed in COVID-19. He also presented data from the analysis of a series of antibodies from COVID-19 patients. Certain antibodies against the NTD were shown to enhance the ACE2 binding and augment the infectivity of SARS-CoV-2. Mutational analysis of the S-protein revealed that all infectivity-enhancing antibodies recognize a specific site on the NTD. Furthermore, all hospitalized patients possessed such infectivity-enhancing antibodies, suggesting that production of the infectivity-enhancing antibodies could be one of the exacerbating factors for COVID-19.

Recognizing the devastating impact of COVID-19 on our society and the global economy, Takanori Kanai (Keio University, Japan) has launched a Task Force of leading academics and experts in the field of clinical medicine in Japan. He said that this timely emergency project 'Corona Suppression Task Force' is required to protect society from the new coronavirus and involves a cross-sectional gathering of scientists representing Japan from various research fields to unravel the objective truth of science. He reported that an urgent goal was the prevention of medical collapse and aimed to develop new coronavirus treatments before such a collapse.

The virulent influenza virus causes a fatal condition when it infects humans, yet no effective treatment for severe influenza has been developed. Yumiko Imai (National Institutes of Biomedical Innovation, Health and Nutrition, Japan) reported the screening of a library of fatty acid metabolites and lipidomic analysis of fatty acid metabolites by mass spectrometry to identify protective metabolites derived from polyunsaturated fatty acids. She reported that the production of anti-inflammatory protectin D1 depends on 12/15 lipoxygenase, which was reduced in severe influenza, especially in lung tissue infected with the virulent H5N1 virus. She is currently screening for influenza virus growth using compounds that regulate the activity of histone-modifying enzymes. Because a similar mechanism seems to be involved in the pathogenesis of COVID-19, such research is expected to lead to the development of new antiviral drugs targeting the epigenome response mechanism of the host during SARS-CoV-2 infection.

Currently, a lot of information regarding the novel coronavirus is available from several sources. However, it is important that everyone has accurate information and that everyone accurately understands the etiology and pathology of COVID-19. This session aimed to share the current knowledge and unresolved issues with respect to COVID-19 and discuss how basic research in the field of immunology contributes to the management of current and future pandemics. This session involved approximately 600 participants, including not only immunologists but also non-immunologists, clinicians and media officials.

First, Masayuki Miyasaka, an Emeritus Professor at Osaka University, gave an overview about the current COVID-19 pandemic. He summarized how the immune system recognizes SARS-CoV-2, the roles of innate and adaptive immune responses in COVID-19 diseases and what we do and do not know about the factors that determine the susceptibility associated with the exacerbation of COVID-19. The lecture was comprehensive and provided essential, highly concentrated information.

Thereafter, five Japanese scientists who are actively conducting cutting-edge research on SARS-CoV-2 or the COVID-19 pandemic in Japan discussed multiple aspects, including SARS-CoV-2 susceptibility among ethnic groups, the immune responses against SARS-CoV-2 and the current state of vaccine/therapeutics development, as well as unresolved issues.

The first topic was on the risk factors in Japanese patients. Professor Takanori Kanai from Keio University first introduced the current state of the 'Joint Research Coronavirus Task Force', which was started in March 2020 with support from the Japan Agency for Medical Research and Development. The aim of this task force was to determine the genetic basis for the mechanisms that aggravate COVID-19. Professor Kanai stated that 950 Japanese patients were analyzed, and the number of subjects is expected to reach 2000 by January 2021. Further, he mentioned that they found some candidate genes that were different from the genes (e.g. CCR9, TLR7 and ACE2) that were identified overseas. On the basis of their analyses, there are high expectations that they will identify genetic susceptibilities unique to Japanese people associated with the aggravation of COVID-19.

In addition to host genetic factors, it is broadly accepted that non-genetic factors, such as age and underlying diseases, have a large influence on the pathogenesis of COVID-19. Yumiko Imai from the National Institutes of Biomedical Innovation, Health and Nutrition introduced her approach for the search of non-genetic factors to determine the severity of COVID-19 symptoms in Japanese patients. She introduced her efforts for establishing a large-scale database with data from asymptomatic patients as well as severely affected patients by gathering information on host factors that influenced the viral dynamics and immune responses, including age, underlying diseases, host and viral genome information, immune repertoire, antibodies and cytokines. She proposed the concept of an 'AI hospital' safely stored in the cloud, wherein an enormous volume of omics and immunological data will be widely shared among academia, industries and hospitals. Such a platform appears to be extremely useful for developing novel therapeutic strategies. However, it is important to thoughtfully deal with important issues to allow efficient use of these databases in terms of what we should focus on and what perspective should be used. Doing so will enable meaningful knowledge to be extracted from large databases in the future.

In addition to the importance of ongoing database projects, Professor Miyasaka pointed out the importance and values of biobanking and emphasized that frozen whole blood samples containing leukocytes-used for analyzing immune responses against SARS-CoV-2-are missing in Japan's biobank system. Such samples, including those from patients and non-infected individuals, are extremely useful for investigating the changes before and after SARS-CoV-2 infection, particularly cellular immunity. Professor Kanai also proposed establishing a continued and sustained system to collect blood samples not only from patients but also from healthy individuals, including those ranging from elementary school-age students to senior citizens.

The next topic concerned the immunological properties of SARS-CoV-2. Yoshimasa Takahashi from the National Institute of Infectious Disease introduced recent data on how long the immunity against SARS-CoV-2 lasts and the current understanding of immune memory against re-infection with SARS-CoV-2. He discussed the accumulating data of antibody decay after SARS-CoV-2 infection and pointed out that there is insufficient information about the levels of antibodies required for protection against re-infecting with SARS-CoV-2. This point might be important for evaluating the efficacy of vaccines. Dr Takahashi further introduced his efforts regarding a profiling and follow-up study of acquired immunity against SARS-CoV-2 in Japanese patients. His group is currently analyzing antigen-specific T cells and B cells with a broad range of techniques, including single-cell transcriptome analyses, epitope analyses and repertoire analyses, to identify critical immunological factors for protection against SARS-CoV-2. There are high expectations that we will obtain valuable information from observations procured through these approaches about what researchers should evaluate to develop more-effective vaccines for eradicating SARS-CoV-2 infection. Additionally, we discussed the efficacy of the bacillus Calmette-Guérin (BCG) vaccine, and Professor Miyasaka introduced a recent study on the relation between BCG strain and severity and/or T h 1 cytokine production in patients with COVID-19 worldwide. Although 'trained' innate immunity is important for protection against COVID-19, there is insufficient understanding regarding its molecular bases. Further research on the significance of BCG vaccine in SARS-CoV-2 infection might reveal a novel role of vaccination and the mechanism for the long-lasting effects of some types of vaccines.

In the context of vaccine development, Ken Ishii from The University of Tokyo conveyed a strong message through his statements. He summarized the landscape of vaccine development, including the competitive environment and what happens throughout the world. He emphasized that people need to be given accurate information about vaccines, rather than rumors circulating in the community, such as those obtained through short message services, the internet and television. He noted that, in Japan, training to learn to collect and analyze accurate information on our own should be promoted. Further, he discussed problems related to financial resources in Japan and analyzed the reasons why vaccine development in Japan is slower than that in other countries. Moreover, he emphasized that vaccine development needs to be performed with complete dedication, i.e. while in other countries, the currently available vaccines might be approved without sufficient basic research, in Japan, some clinical trials are ongoing and immunityrelated evidence is being accumulated in parallel at a satisfactory pace. Professor Ishii also conveyed a meaningful message regarding the importance of the vaccine in terms of its significance for public health, the equality of vaccine distribution and the risk of excessive hesitancy about vaccine usage in the current COVID-19 pandemic. Many attendants heard his critical alerts and realized the importance of determining one's attitude as per one's conscience. Professor Ishii's last opinion was impressive in that human immunological studies should be encouraged as much as possible in Japan.

The COVID-19 pandemic has revealed several problems, including political measures and the framework of academia. Researchers have realized, through the lens of the COVID-19 pandemic, how they should proceed with research and how immunologists need to contribute to the fight against emerging infectious microbes. This panel discussion was an excellent opportunity for all of us to share our knowledge and experiences.

Finally, Toshiaki Ohteki from Tokyo Medical and Dental University, Japan, who was the steering committee chair of this 49th Japanese Society for Immunology meeting, made a closing remark. His powerful statement, 'I am confident that the power of immunology will overcome COVID-19 in the near feature' anchored all the participants' minds toward a bright future.

Conflicts of interest statement: the authors declared no conflicts of interest.

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA